Immune–tumor cell ligand–receptor axes driving metabolic reprogramming and therapeutic resistance in cancer - Takeaways - MDSpire

Immune–tumor cell ligand–receptor axes driving metabolic reprogramming and therapeutic resistance in cancer

  • By

  • Hailin Zhu

  • Wang Yi

  • Yujie Wu

  • Rong Li

  • Boxuan Zhou

  • June 16, 2026

  • 0 min

Share

  • 1

    Therapeutic resistance in cancer is influenced by immune-tumor ligand-receptor signaling, not just tumor-intrinsic factors.

  • 2

    Immune cells actively shape tumor behavior through metabolic reprogramming, promoting proliferation and therapy resistance.

  • 3

    Lactate signaling and checkpoint pathways integrate immune suppression with tumor metabolic adaptation and treatment failure.

  • 4

    Targeting immune-tumor communication alongside metabolic dependencies may help overcome resistant tumor niches.

  • 5

    Advancements in technologies are enhancing our understanding of immune-tumor interactions and their role in therapeutic resistance.

Original Source(s)

Immune–tumor cell ligand–receptor axes driving metabolic reprogramming and therapeutic resistance in cancer

  • by Hailin Zhu, Wang Yi, Yujie Wu, Rong Li, Boxuan Zhou

  • June 16, 2026

Related Content

Editorial: Understanding oral health challenges in pediatric and adult cancer care

Correction: miR-17: from developmental regulatory hub to molecular engine driving tumourigenesis

Case Report: Long-term maternal and neonatal outcomes after nivolumab therapy in metastatic tonsillar sarcomatoid squamous cell carcinoma